Profil
Harvey N.
Masonson held several positions in the pharmaceutical industry, including Assistant Director-Clinical Safety at Bristol Myers Squibb Co., Director-Clinical Research at Sanofi-Synthelabo, Inc., Vice President-Clinical Development & Drug Safety at (OSI).
Eyetech, and Senior Vice President-Clinical Development at IVERIC bio, Inc. He also served as Vice President-Clinical Development at Gensight Biologics SA from 2018 to 2019.
Masonson earned a doctorate degree from the Icahn School of Medicine at Mount Sinai.
Ehemalige bekannte Positionen von Harvey N. Masonson
| Unternehmen | Position | Ende |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology Provides medical services | Corporate Officer/Principal | - |
Sanofi-Synthelabo, Inc. | Technik-/Wissenschafts-/F&E-Leiter | - |
| IVERIC BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Harvey N. Masonson
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology Provides medical services | Health Technology |
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IVERIC bio, Inc.
IVERIC bio, Inc. BiotechnologyHealth Technology Operates as a science-driven biopharmaceutical company that develops novel treatments for retinal diseases | Health Technology |
Sanofi-Synthelabo, Inc. | Health Technology |
Gensight Biologics SA
Gensight Biologics SA Pharmaceuticals: MajorHealth Technology Manufactures and markets novel therapies for severe retinal neurodegenerative diseases | Health Technology |
















